Allspring Global Investments Holdings LLC Sells 3,844 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Allspring Global Investments Holdings LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,630 shares of the biopharmaceutical company's stock after selling 3,844 shares during the period. Allspring Global Investments Holdings LLC's holdings in Regeneron Pharmaceuticals were worth $24,452,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock worth $675,000 after acquiring an additional 686 shares during the last quarter. SVB Wealth LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $707,000. Fisher Asset Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 16.5% during the 4th quarter. Fisher Asset Management LLC now owns 5,890 shares of the biopharmaceutical company's stock valued at $4,197,000 after purchasing an additional 833 shares during the last quarter. US Bancorp DE boosted its holdings in shares of Regeneron Pharmaceuticals by 21.6% during the 4th quarter. US Bancorp DE now owns 6,066 shares of the biopharmaceutical company's stock valued at $4,321,000 after purchasing an additional 1,078 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its position in shares of Regeneron Pharmaceuticals by 8.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 952 shares of the biopharmaceutical company's stock valued at $669,000 after purchasing an additional 72 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.5%

Shares of REGN traded down $2.74 during trading hours on Thursday, reaching $545.00. 456,413 shares of the company traded hands, compared to its average volume of 905,431. The stock's fifty day moving average price is $551.63 and its 200 day moving average price is $628.53. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a market cap of $58.84 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.01 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm earned $9.55 earnings per share. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday. The Goldman Sachs Group cut their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research report on Friday, May 30th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $822.58.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.